NECTIN4: Nectin-4
Seems to be involved in cell adhesion through trans- homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on NECTIN4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate 1
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Enfortumab vedotinBoxed warning | Approved | Astellas Pharma | Antibody-drug conjugate | Binding agentNectin-4 binding agent | 94 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Ectodermal dysplasia-syndactyly syndrome
- 0.78
- Urothelial carcinoma
- 0.52
- Neoplasm
- 0.40
- Urinary bladder carcinoma
- 0.38
- Transitional cell carcinoma
- 0.37
- Cancer
- 0.35
- Urogenital neoplasm
- 0.33
- Amelogenesis imperfecta
- 0.18
- Hereditary disease
- 0.16
- Breast cancer
- 0.12
- Ovarian cancer
- 0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712928, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q96NY8, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets